Hello, Guest
Login
Sign Up
 
 

Hot Nonwinners News (OIBR, IPXL, ARNA, NBG)

PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.

 
 
Repost This

New York, NY -- (SBWIRE) -- 01/22/2013 -- Oi SA (ADR) (NYSE:OIBR) shares fell 1.84% to $4.42 in the previous trading session. The 52 week trading range for the company is $3.62 – $7.04. The shares of the company fell 12% in the last one year. The company is a Brazil-based holding company engaged in the telecommunication sector. The Company is primarily involved in the provision of fixed telephony services in the Brazilian states of Acre, Rondonia, Mato Grosso, Mato Grosso do Sul, Tocantins, Goias, Parana, Santa Catarina and Rio Grande do Sul.

Is OIBR Showing Any Sign of Buy At The Current Market Price? Get Our Free Trend Analysis Here

Shares of Impax Laboratories (NASDAQ:IPXL) opened at 21.02 on Tuesday. Impax Laboratories have a 52 week low of $18.40 and a 52 week high of $27.25. The stock’s 50-day moving average is currently $20.82. The company has a market cap of $1.388 billion and a P/E ratio of 19.66.

Impax Laboratories last announced its earnings results on Tuesday, October 30th. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.49 by $0.01. The company had revenue of $145.60 million for the quarter, compared to the consensus estimate of $160.76 million. The company’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, analysts predict that Impax Laboratories will post $1.79 earnings per share for the current fiscal year.

How Should Investors Trade IPXL Now? Find Out Here

Arena Pharmaceuticals Inc (NASDAQ:ARNA) moved down 6.51% and closed at $9.77 on a traded volume of 20.32 million shares. Arena Pharmaceuticals has been restated by TheStreet Ratings as a sell with a ratings score of D- . Arena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Is it the Right to Grab ARNA after the Recent Slump? Get Free Trend Analysis Here

National Bank of Greece (ADR) (NYSE:NBG) decreased 6.59% and closed at $1.56 on a traded volume of 3.86 million shares. National Bank of Greece SA and Eurobank Ergasias SA has asked authorities to delay picking a buyer for TT Hellenic Postbank S.A. until their transaction is complete. NBG wants to avoid the Postbank race complicating NBG’s tender offer to Eurobank shareholders, which was launched in October before the bank expressed its interest in the state lender. The financial terms of the deal were not disclosed.

Will NBG Bounce Back After yesterday’s Sharp Sell off? Find Out Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz